About Patrick Ryan
Patrick Ryan has invested in stocks and traded options for more than a decade. He specializes in growth stocks, with a particular focus on those in the technology and entertainment sectors. Patrick began writing for StockNews.com in 2019. His mission is to pinpoint growth stocks trading at attractive prices. This requires a focus on the fundamentals including in-depth qualitative and quantitative analysis. Patrick often abides by a contrarian market strategy as he analyzes investment opportunities with irreverence for conventional logic. This often leads to finding hidden gems with tremendous long term upside potential.
Recent Articles By Patrick Ryan
Foresight vs. Magna: Which Autonomous Vehicle Stock is a Better Buy
Foresight Autonomous Holdings (FRSX) and Magna International (MGA) are two autonomous vehicle stocks. Both are down over the last 3 months amid the selloff in growth stocks. Is it time to buy? Patrick Ryan gives his take.
Viatris: Buy or Sell?
Viatris (VTRS) is a pharmaceutical company that sells a variety of different drugs. The company plans to offer its first ever dividend and is currently trading at a very low valuation. Does that make it a Buy? Read more to find out.
Up 20% in the Last Month, is NortonLifeLock Still a Buy?
NortonLifeLock (NLOK) has been an outperformer over the past month, when many tech stocks have had sharp pullbacks. Patrick Ryan gives his take on whether NLKOK remains a buy following a 20% gain.
Down 25% YTD, Should Investors Scoop Up Shares of COMPASS Pathways?
Healthcare companies are continuously looking for new treatment options for patients. One in particular, COMPASS Pathways (CMPS), is focused on using psilocybin therapy treat depression. The stock has generated a lot of interest, but is down 25% for the year. Is it time to buy? Read more to find out.
Are Shares of Coinbase a Good Buy Under $250?
Coinbase (COIN) is down 32% since its IPO. The losses have intensified in recent days due to weakness in bitcoin. Is it time to buy the dip or is this the beginning of a bearish trend in cryptocurrencies?
Avoid These 3 Sell-Rated Stocks at All Costs
The market's recently volatility has made some investors step back and think about their holdings. While this bout of volatility may be temporary, it's always good to stick to stocks that have a higher potential for outperformance and avoid stocks that have a higher potential for underperformance. That's why you should avoid recently downgraded stocks such as Cardlytics (CDLX), CorMedix (CRMD), and fuboTV (FUBO).
3 Buy-Rated Stocks Poised to Soar Higher
The market has been on the quite the ride over the past week, which is why investors should only consider stocks that are likely to outperform. Our POWR Ratings system evaluates stocks based on 118 different factors to find the best of the best. Tempur Sealy (TPX), Shuttershock (SSTK), and Computer Programs & Systems (CPSI) are three that were recently upgraded to Strong Buy in the POWR Ratings system and deserve a look.
Should Investors Buy the Dip in Trade Desk?
The Trade Desk’s (TTD) stock declined more than 25% in a single day following the company's latest earnings report. Because the stock dipped 50% below its yearly high, it could be a fantastic buying opportunity for investors who have been patiently waiting on the sidelines. So, is TTD worthy of their investing dollars now that it is available at a considerable discount? Read on for an answer.
Should Investors Buy the Post-Earnings Dip in Facebook?
Facebook (FB) continues to broaden its horizons by diversifying its revenue streams across social media, virtual reality, online transactions and possibly even its own cryptocurrency at some point in the future. Though the stock has gyrated this month, top analysts are bullish on the name in-part due to its diversified revenue streams. So, is the stock an attractive buy now in the wake of a post-earnings report dip? Read on to find out.